CAI logo

CARIS LIFE SCIENCES INC

CAINASDAQ
🏆 #869 by market capEarnings Nov 4 · PostUS Equity
$35.44▲ $1.76 (+5.24%)
Pre-market · at close
🔔
Track CAI
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.2%
7d▲ 11.8%
14d▲ 11.6%
30d▲ 12.3%
ytd▲ 31.4%
1y▲ 20.5%
🏦Market Cap
$10.02B
Mid Cap
📈Revenue Growth (YoY)
38.5%
High Growth
📊Gross Margin
69.7%
High
💵FCF Margin
12.5%
Healthy
⚖️P/S Ratio
9.3x
Elevated
Otter Score
76
Strong

Trading Snapshot

Day Range
$33.49 – $36.38
52-Week Range
$14.19 – $33.13
Volume (shares)
262,449
Avg Volume (shares)
—
Shares Outstanding
282.6M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$812M
Last Q Revenue
$264M
P/E Ratio
87.2
P/S Ratio
9.3x
EPS (TTM)
$0.37
Dividend Yield
—
Dilution (1yr)
+3.1%
CAI logo

CARIS LIFE SCIENCES INC

CAI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$812M▲ +97.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
66.4%▲ +53.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$45M▼ −117.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$67M▼ −126.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
289.9M▲ +3.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$419M▲ +$779M YoY
StockOtter · stockotter.space

About CARIS LIFE SCIENCES INC

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
76/100

Analyst Ratings

ⓘ
Consensus
Buy
16 analysts
Strong Buy6
Buy6
Hold4
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.